| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
COH Stock Overview
Cochlear Limited provides implantable hearing solutions for adults and children worldwide.
Rewards
Risk Analysis
No risks detected for COH from our risk checks.
Cochlear Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$223.85 |
| 52 Week High | AU$257.76 |
| 52 Week Low | AU$178.55 |
| Beta | 0.38 |
| 1 Month Change | 10.73% |
| 3 Month Change | 3.40% |
| 1 Year Change | -10.19% |
| 3 Year Change | 6.47% |
| 5 Year Change | 59.70% |
| Change since IPO | 7,488.14% |
Recent News & Updates
The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
A Look At The Fair Value Of Cochlear Limited (ASX:COH)
In this article we are going to estimate the intrinsic value of Cochlear Limited ( ASX:COH ) by projecting its future...
Shareholder Returns
| COH | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 4.5% | 4.7% | 1.0% |
| 1Y | -10.2% | -17.2% | -7.9% |
Return vs Industry: COH exceeded the Australian Medical Equipment industry which returned -17.2% over the past year.
Return vs Market: COH underperformed the Australian Market which returned -7.9% over the past year.
Price Volatility
| COH volatility | |
|---|---|
| COH Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 11.5% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 4.7% |
Stable Share Price: COH is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: COH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,000 | Dig Howitt | https://www.cochlear.com |
Cochlear Limited provides implantable hearing solutions for adults and children worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
Cochlear Fundamentals Summary
| COH fundamental statistics | |
|---|---|
| Market Cap | AU$14.72b |
| Earnings (TTM) | AU$260.10m |
| Revenue (TTM) | AU$1.58b |
56.6x
P/E Ratio9.3x
P/S RatioIs COH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COH income statement (TTM) | |
|---|---|
| Revenue | AU$1.58b |
| Cost of Revenue | AU$408.70m |
| Gross Profit | AU$1.17b |
| Other Expenses | AU$906.30m |
| Earnings | AU$260.10m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 19, 2022
| Earnings per share (EPS) | 3.95 |
| Gross Margin | 74.05% |
| Net Profit Margin | 16.51% |
| Debt/Equity Ratio | 2.7% |
How did COH perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield75%
Payout RatioValuation
Is COH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for COH?
Other financial metrics that can be useful for relative valuation.
| What is COH's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | AU$14.72b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.2x |
| Enterprise Value/EBITDA | 34.4x |
| PEG Ratio | 5.2x |
Price to Earnings Ratio vs Peers
How does COH's PE Ratio compare to its peers?
| COH PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 53.9x | ||
RHC Ramsay Health Care | 45.1x | 21.7% | AU$16.8b |
SHL Sonic Healthcare | 11.5x | -16.4% | AU$16.8b |
ANN Ansell | 11.1x | 4.1% | AU$3.5b |
PME Pro Medicus | 148.1x | 21.3% | AU$5.6b |
COH Cochlear | 56.6x | 10.9% | AU$14.7b |
Price-To-Earnings vs Peers: COH is expensive based on its Price-To-Earnings Ratio (56.6x) compared to the peer average (53.9x).
Price to Earnings Ratio vs Industry
How does COH's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: COH is expensive based on its Price-To-Earnings Ratio (56.6x) compared to the Global Medical Equipment industry average (24.1x)
Price to Earnings Ratio vs Fair Ratio
What is COH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 56.6x |
| Fair PE Ratio | 34.7x |
Price-To-Earnings vs Fair Ratio: COH is expensive based on its Price-To-Earnings Ratio (56.6x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).
Share Price vs Fair Value
What is the Fair Price of COH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: COH (A$223.85) is trading above our estimate of fair value (A$197.08)
Significantly Below Fair Value: COH is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Future Growth
How is Cochlear forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
10.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COH's forecast earnings growth (10.9% per year) is above the savings rate (1.8%).
Earnings vs Market: COH's earnings (10.9% per year) are forecast to grow faster than the Australian market (6.2% per year).
High Growth Earnings: COH's earnings are forecast to grow, but not significantly.
Revenue vs Market: COH's revenue (8.6% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: COH's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COH's Return on Equity is forecast to be low in 3 years time (19.1%).
Discover growth companies
Past Performance
How has Cochlear performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-13.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COH has high quality earnings.
Growing Profit Margin: COH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: COH's earnings have declined by 13.3% per year over the past 5 years.
Accelerating Growth: COH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: COH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).
Return on Equity
High ROE: COH's Return on Equity (15%) is considered low.
Discover strong past performing companies
Financial Health
How is Cochlear's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: COH's short term assets (A$1.2B) exceed its short term liabilities (A$377.6M).
Long Term Liabilities: COH's short term assets (A$1.2B) exceed its long term liabilities (A$324.6M).
Debt to Equity History and Analysis
Debt Level: COH has more cash than its total debt.
Reducing Debt: COH's debt to equity ratio has reduced from 35.5% to 2.7% over the past 5 years.
Debt Coverage: COH's debt is well covered by operating cash flow (651.6%).
Interest Coverage: COH's interest payments on its debt are well covered by EBIT (51.1x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Cochlear current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
1.38%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: COH's dividend (1.38%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.62%).
High Dividend: COH's dividend (1.38%) is low compared to the top 25% of dividend payers in the Australian market (6.24%).
Stability and Growth of Payments
Stable Dividend: COH is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: COH is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: COH is not paying a notable dividend for the Australian market.
Cash Payout to Shareholders
Cash Flow Coverage: COH is not paying a notable dividend for the Australian market.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
6.1yrs
Average management tenure
CEO
Dig Howitt (55 yo)
5.08yrs
Tenure
AU$4,861,997
Compensation
Mr. Diggory William Howitt, also known as Dig, BE (Hons), MBA has been President of Cochlear Limited since July 31, 2017 and its Chief Executive Officer and Managing Director since January 3, 2018. Mr. How...
CEO Compensation Analysis
Compensation vs Market: Dig's total compensation ($USD3.35M) is about average for companies of similar size in the Australian market ($USD3.99M).
Compensation vs Earnings: Dig's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: COH's management team is seasoned and experienced (6.1 years average tenure).
Board Members
Experienced Board: COH's board of directors are considered experienced (5.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Cochlear Limited's employee growth, exchange listings and data sources
Key Information
- Name: Cochlear Limited
- Ticker: COH
- Exchange: ASX
- Founded: 1981
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: AU$14.724b
- Shares outstanding: 65.78m
- Website: https://www.cochlear.com
Number of Employees
Location
- Cochlear Limited
- 1 University Avenue
- Macquarie University
- Sydney
- New South Wales
- 2109
- Australia
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/07 00:00 |
| End of Day Share Price | 2022/08/05 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.